Development of interferon γ-based immunocytokines targeting renal cancer

Abstract

Advanced renal cancer is an incurable malignancy in need of novel therapeutic avenues. We have generated interferon γ(IFNγ)-based fusion antibodies (immunocytokines) that target CD70, a putative biomarker of renal cancer. These immunocytokines efficiently labeled renal cancer cells, and, when combined with the proteasome inhibitor bortezomib, killed them by activating a RIP1-dependent necrotic pathway. © 2013 Landes Bioscience.